JP2013508353A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013508353A5 JP2013508353A5 JP2012535106A JP2012535106A JP2013508353A5 JP 2013508353 A5 JP2013508353 A5 JP 2013508353A5 JP 2012535106 A JP2012535106 A JP 2012535106A JP 2012535106 A JP2012535106 A JP 2012535106A JP 2013508353 A5 JP2013508353 A5 JP 2013508353A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- autoimmune disease
- nucleotide sequence
- sequence encoding
- mesenchymal stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000023275 Autoimmune disease Diseases 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 11
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 10
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 10
- 239000002773 nucleotide Substances 0.000 claims 10
- 125000003729 nucleotide group Chemical group 0.000 claims 10
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 9
- 206010025135 lupus erythematosus Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 210000000068 Th17 cell Anatomy 0.000 claims 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000003289 regulatory T cell Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 102100030886 Complement receptor type 1 Human genes 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020090101194A KR101301262B1 (ko) | 2009-10-23 | 2009-10-23 | ＴＧＦβ를 코딩하는 뉴클레오티드 서열이 도입된 간엽줄기세포 및 그의 용도 |
| KR10-2009-0101194 | 2009-10-23 | ||
| PCT/KR2010/005771 WO2011049291A2 (ko) | 2009-10-23 | 2010-08-27 | ＴＧＦβ를 코딩하는 뉴클레오티드 서열이 도입된 간엽줄기세포 및 그의 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013508353A JP2013508353A (ja) | 2013-03-07 |
| JP2013508353A5 true JP2013508353A5 (enExample) | 2013-04-25 |
Family
ID=43900765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012535106A Pending JP2013508353A (ja) | 2009-10-23 | 2010-08-27 | ＴＧＦβをコーディングするヌクレオチド配列が導入された間葉系幹細胞及びその用途 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20120207725A1 (enExample) |
| JP (1) | JP2013508353A (enExample) |
| KR (1) | KR101301262B1 (enExample) |
| WO (1) | WO2011049291A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201202319D0 (en) | 2012-02-10 | 2012-03-28 | Orbsen Therapeutics Ltd | Stromal stem cells |
| CA3205855A1 (en) | 2013-04-16 | 2014-10-23 | Orbsen Therapeutics Limited | Medical use of syndecan-2 |
| KR20150016117A (ko) * | 2013-07-30 | 2015-02-11 | 코아스템(주) | 인간 골수 유래 중간엽 줄기세포를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약제학적 조성물 |
| KR101659158B1 (ko) * | 2013-08-16 | 2016-09-23 | 가톨릭대학교 산학협력단 | 메트포민이 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 |
| WO2015023165A1 (ko) * | 2013-08-16 | 2015-02-19 | 가톨릭대학교 산학협력단 | 염증조절복합체 및 ｓｔａｔ３ 신호분자 차단을 통한 면역조절능 최적화된 안정화 중간엽줄기세포 |
| KR20160024147A (ko) | 2014-08-25 | 2016-03-04 | 가톨릭대학교 산학협력단 | 강화된 인터류킨―１ 수용체 길항제 생성능을 보유한 중간엽 줄기세포의 제조방법 |
| JP6475847B2 (ja) * | 2015-02-06 | 2019-02-27 | コーロン ライフ サイエンス インコーポレイテッドＫｏｌｏｎ Ｌｉｆｅ Ｓｃｉｅｎｃｅ， Ｉｎｃ． | 過免疫反応によって誘発される炎症性疾患治療用組成物 |
| EP3271396B1 (en) | 2015-03-20 | 2022-03-16 | Orbsen Therapeutics Limited | Modulators of syndecan-2 and uses thereof |
| EP3402489B1 (en) | 2016-01-15 | 2021-06-09 | Orbsen Therapeutics Limited | Sdc-2 exosome compositions and methods of isolation and use |
| JP2017200473A (ja) * | 2016-04-27 | 2017-11-09 | 株式会社Ｃｅｌｌｓ Ｐｏｗｅｒ | 活性化幹細胞 |
| US20230111840A1 (en) * | 2017-01-30 | 2023-04-13 | Kyoto University | Compound, And Method For Producing Regulatory T Cells |
| JP7174758B2 (ja) | 2017-07-14 | 2022-11-17 | オーブセン セラピューティクス リミテッド | Ｃｄ３９間質幹細胞の単離方法と使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| EP2298863B1 (en) * | 2004-03-22 | 2015-07-22 | Mesoblast International Sàrl | Mesenchymal stem cells and uses therefor |
| US20070253931A1 (en) * | 2006-01-12 | 2007-11-01 | Osiris Therapeutics, Inc. | Use of mesenchymal stem cells for treating genetic diseases and disorders |
| CA2649440A1 (en) * | 2006-04-12 | 2007-10-25 | Genzyme Corporation | Methods of treating autoimmune diseases |
| US20090104155A1 (en) * | 2006-04-21 | 2009-04-23 | Goodrich Laurie R | Treatment of connective tissue disorders |
| JP2008162983A (ja) * | 2006-12-28 | 2008-07-17 | Japan Science & Technology Agency | プロジェクターを使った機能的神経ネットワーク構築方法 |
| JP2009001509A (ja) * | 2007-06-19 | 2009-01-08 | Univ Nagoya | 脂肪組織由来幹細胞を用いた組織再生用組成物 |
-
2009
- 2009-10-23 KR KR1020090101194A patent/KR101301262B1/ko active Active
-
2010
- 2010-08-27 US US13/503,390 patent/US20120207725A1/en not_active Abandoned
- 2010-08-27 JP JP2012535106A patent/JP2013508353A/ja active Pending
- 2010-08-27 WO PCT/KR2010/005771 patent/WO2011049291A2/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013508353A5 (enExample) | ||
| Kwon et al. | State of the art: the immunomodulatory role of MSCs for osteoarthritis | |
| Alvites et al. | Mesenchymal stem/stromal cells and their paracrine activity—immunomodulation mechanisms and how to influence the therapeutic potential | |
| Park et al. | Graphene-regulated cardiomyogenic differentiation process of mesenchymal stem cells by enhancing the expression of extracellular matrix proteins and cell signaling molecules. | |
| WO2017011804A8 (en) | Engineered cells for adoptive cell therapy | |
| Dunavin et al. | Mesenchymal stromal cells: what is the mechanism in acute graft-versus-host disease? | |
| EP4219725A3 (en) | Altering gene expression in modified t cells and uses thereof | |
| Greiner et al. | Immunological and clinical impact of manipulated and unmanipulated DLI after allogeneic stem cell transplantation of AML patients | |
| MY189819A (en) | Genetically modified cells and uses thereof | |
| HK1203219A1 (en) | Method of treatment employing therapeutic t cell product from mobilised donors | |
| WO2016011210A3 (en) | Engineered cells for adoptive cell therapy | |
| WO2011139628A8 (en) | Generation of anterior foregut endoderm from pluripotent cells | |
| BR112013031262A2 (pt) | "exotoxinas a de pseudomonas com menos epítopos imunogênicos de célula b e t, e seu uso no tratamento e prevenção de câncer, bem como molécula quimérica, ácido nucleico, vetor de expressão, células, composição farmacêutica e métodos para inibir crescimento de célula-alvo e de produção de endotoxinas a de pseudomonas e de molécula quimérica". | |
| WO2010051634A9 (en) | Human progenitor t-cells | |
| Magatti et al. | Perinatal mesenchymal stromal cells and their possible contribution to fetal-maternal tolerance | |
| Shimizu et al. | Management of rheumatoid arthritis: possibilities and challenges of mesenchymal stromal/stem cell-based therapies | |
| JP2016501515A5 (enExample) | ||
| Du et al. | Hypoxia enhances protective effect of placental-derived mesenchymal stem cells on damaged intestinal epithelial cells by promoting secretion of insulin-like growth factor-1 | |
| Saparov et al. | The role of antioxidation and immunomodulation in postnatal multipotent stem cell-mediated cardiac repair | |
| EA033437B1 (ru) | Fc-гамма-рецептор iib и его применение для лечения или предупреждения воспалительных и/или аутоиммунных заболеваний | |
| WO2012075462A3 (en) | Methods and compositions for treatment of muscular dystrophy | |
| PL399447A1 (pl) | Szczepionka do leczenia cukrzycy typu 1 u dzieci, zastosowanie sortera komórek oraz sposób namnazania komórek Treg do wytwarzania szczepionki do leczenia cukrzycy typu 1 | |
| WO2010045573A3 (en) | Tumor vaccine | |
| Giallongo et al. | Engagement of Mesenchymal stromal cells in the remodeling of the bone marrow microenvironment in hematological cancers | |
| JP2016510766A5 (enExample) |